BeOne Medicines Ltd. business relationships

“Additionally, we have agreed to use reasonable best efforts to provide Amgen with an opportunity to participate in subsequent new securities offerings upon the same terms and conditions as other purchasers in the offering in an amount needed to allow Amgen to hold up to 20.6% of our shares, subject...” SEC filing

“The repayment of this obligation to Royalty Pharma will be made upon the receipt of royalties from Amgen throughout the royalty period.” SEC filing

“Under our license agreement with Amgen, Amgen retains the responsibility, but is not obligated, to prosecute, defend and enforce the patents for the corresponding in-licensed products.” SEC filing

“In-Licensed Products from Bristol-Myers Squibb Company ("BMS")” SEC filing

“In January 2021, the Company entered into a collaboration and license agreement with Novartis, granting Novartis rights to develop, manufacture and commercialize tislelizumab in North America, Europe, and Japan (the "Novartis Territory").” SEC filing

“Amgen co-development expenses 1” SEC filing

“...ty revenue from IMDELLTRA ® sales outside of China under the Amgen collaboration agreement, revenue generated under the Novartis broad markets agreement, and research and development services revenue and right to access intellectual property revenue from its former collaboration agreements with Nova...” SEC filing

“We do not have any minimum purchase requirements for inventory from Amgen.” SEC filing

“We became a commercial-stage company in 2017, when we entered into a license and supply agreement with Celgene Logistics Sàrl, now a Bristol-Myers Squibb Company ("BMS"), to commercialize three of BMS's approved cancer therapies, in the People's Republic of China ("PRC" or "China").” SEC filing

“For example, we have entered into a commercial supply agreement for TEVIMBRA with Boehringer Ingelheim Biopharmaceuticals (China) Ltd. ("Boehringer Ingelheim") and entered into a commercial supply agreement for BRUKINSA with Catalent Pharma Solutions, LLC ("Catalent").” SEC filing

“...he year ended December 31, 2025, sales to the Company ' s three largest product distributors, ASD Specialty Healthcare (Cencora), McKesson and Shanghai Pharmaceutical represented approximately 18.5 %, 17.5 % and 10.1 % of product revenue, respectively, and collectively, represented approximately 37....” SEC filing

“...ded December 31, 2025, sales to the Company ' s three largest product distributors, ASD Specialty Healthcare (Cencora), McKesson and Shanghai Pharmaceutical represented approximately 18.5 %, 17.5 % and 10.1 % of product revenue, respectively, and collectively, represented approximately 37.1 % of tra...” SEC filing

“Under the terms of the Royalty Agreement, we received a non-refundable upfront payment of $885 million upon the closing of the Royalty Agreement, and subsequently exercised our option to sell to Royalty Pharma an additional portion of our rights to royalty payments for approximately $26 million.” SEC filing

“The repayment of this obligation to Royalty Pharma will be made upon the receipt of royalties from Amgen throughout the royalty period.” SEC filing

“Under our license and collaboration agreement with Zymeworks Inc. ("Zymeworks"), we have the right to develop and commercialize ZIIHERA ® in certain Asian pacific countries.” SEC filing

“BG-68501 is licensed from Ensem Therapeutics, Inc.” SEC filing

“Third Amendment to Collaboration Agreement, dated October 31, 2025, by and among Amgen Inc., BeOne Medicines I GmbH, and BeOne Medicines Ltd. (portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or co...” SEC filing

“...a 30 % interest in future royalties from the license agreements with Jazz Pharmaceuticals Ireland Limited ("Jazz") and BeOne Medicines Ltd. ("BeOne") relating to Ziihera (zanidatamab‑hrii), not to exceed 120 % of the maximum amount payable (excluding indemnification and other similar obligations) b...” SEC filing